logo

For the Inventor, By the Inventor

Huntington Beach, CA, United States of America

George R Ehring

This inventor holds 15 USPTO granted patents and 2 published patent applications, primarily in Sodium Channel Blockers. Top assignee: Allergan, Inc.. Active years: 2002-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: George R Ehring. Retrieved from https://idiyas.com/inventor/george-r-ehring

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 73.3

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 67(Granted Patents)


Company Filing History:

goldMedal15 out of 2,287 
 
Allergan, Inc.
 patents

Years Active: 2002-2017

Loading Chart...
Areas of Expertise:
Benzimidazole Derivatives
Selective Antagonists
Persistent Sodium Current
Neurological Disorders
Pain Treatment
High-Throughput Screening
Channel Blockers
Na+/Ca2+ Exchanger
Optic Neuropathy
Glaucoma
15 patents (USPTO):Explore Patents
1. 9540332 - Benzimidazole derivatives as selective blockers of persistent sodium current (2017-01-10),
2. 8859780 - Benzimidazole derivatives as selective blockers of persistent sodium current (2014-10-14),
3. 8153645 - Treating pain using selective antagonists of persistent sodium current (2012-04-10),
4. 8124612 - Treating neurological disorders using selective antagonists of persistent sodium current (2012-02-28),
5. 7767718 - Treating pain using selective antagonists of persistent sodium current (2010-08-03),
6. 7763651 - Treating pain using selective antagonists of persistent sodium current (2010-07-27),
7. 7754440 - High-throughput screen for identifying selective persistent sodium channels channel blockers (2010-07-13),
8. 7728034 - Treating neurological disorders using selective antagonists of persistent sodium current (2010-06-01),
9. 7723053 - High-throughput screen for identifying selective persistent sodium channels channel blockers (2010-05-25),
10. 7705055 - Treating neurological disorders using selective antagonists of persistent sodium current (2010-04-27),
11. 7361478 - High-throughput screen for identifying selective persistent sodium channels channel blockers (2008-04-22),
12. 7125908 - Treating pain using selective antagonists of persistent sodium current (2006-10-24),
13. 7060723 - Treating neurological disorders using selective antagonists of persistent sodium current (2006-06-13),
14. 6991910 - High-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels (2006-01-31),
15. 6479458 - Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy (2002-11-12),

Title: The Innovative Mind of George R. Ehring: A Trailblazer in Pharmaceutical Patents

Introduction: George R. Ehring is a prominent inventor based in Huntington Beach, California, known for her significant contributions to the field of pharmaceuticals. With an impressive portfolio of 15 patents, she stands at the forefront of innovative research and development, particularly in the area of selective sodium current blockers.

Latest Patents: Among her latest inventions are notable patents related to benzimidazole derivatives that serve as selective blockers of persistent sodium currents. These compounds represent a significant advancement in the treatment of various conditions mediated by elevated persistent sodium currents, including ocular disorders, multiple sclerosis, seizure disorders, and chronic pain. The pharmaceutical compositions developed from her innovations hold the potential for transformative treatments in these challenging medical areas.

Career Highlights: George R. Ehring has made her mark in the pharmaceutical industry primarily through her work at Allergan, Inc. Her career reflects a dedication to research and innovation, resulting in the development of multiple compounds that can address critical health issues faced by patients today. Her impactful work in pharmacology speaks to her status as a leading inventor.

Collaborations: Throughout her career, George has collaborated with several esteemed colleagues, including Joseph S. Adorante and Larry Allen Wheeler. These relationships have fostered a productive environment for innovation, where ideas can be shared and developed into groundbreaking inventions.

Conclusion: George R. Ehring exemplifies the spirit of innovation within the pharmaceutical sector. Her extensive patent portfolio underscores her commitment to enhancing health outcomes through scientific advancement. As she continues her work at Allergan, her contributions are likely to leave a lasting impact on medicine and patient care for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…